Drug Profile


Alternative Names: Albumin/somatropin fusion protein; Albutropin; Human Growth Hormone Therapy - Teva; Somatropin/albumin fusion protein; TV-1106

Latest Information Update: 20 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 May 2016 Teva Pharmaceutical terminates a phase II trial in Somatotropin deficiency (In children, Treatment-naive) in Bulgaria, Belarus, Czech Republic, Greece, Hungary, Romania, Russia, Ukraine, Serbia, Spain, Georgia, Poland, Israel and Turkey (NCT02092077)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (In adults) in USA (SC) (NCT02410356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top